The species identification of members of the Mycobacterium tuberculosis complex is critical to the timely initiation of both appropriate antibiotic therapy and proper public health control measures. However, the current commercially available molecular assays identify mycobacteria only to the complex level and are unable to differentiate M. tuberculosis from the closely related M. bovis and M. bovis BCG. We describe here a rapid and robust two-step, multiplex, real-time PCR assay based on genomic deletions to definitively identify M. tuberculosis, M. bovis, M. bovis BCG, and other members of the complex. When tested against a panel of well-characterized mycobacterial reference strains, the assay was both sensitive and specific, correctly identifying all strains. We applied this assay to 60 clinical isolates previously identified as M. tuberculosis complex and found 57 M. tuberculosis isolates and 3 M. bovis BCG isolates from patients who had received intravesical BCG. Furthermore, analysis of 15 clinical specimens previously identified as M. bovis by spoligotyping revealed an isolate of M. tuberculosis that had been misidentified. We propose that this assay will allow the routine identification of M. tuberculosis complex members in the clinical laboratory.Tuberculosis is a global health epidemic resulting in significant morbidity and the deaths of ϳ2 million people per year (28). This devastating disease is caused by members of the Mycobacterium tuberculosis complex (MTC), a group of closely related species and subspecies that includes M. tuberculosis, M. bovis, the causative agent of bovine tuberculosis, and M. bovis BCG, the live, attenuated tuberculosis vaccine strain (15).It is important to identify isolates of the MTC to the species level for epidemiologic and public health considerations and to optimize treatment (26). Though M. tuberculosis is the most common cause of tuberculosis in humans, M. bovis accounts for 0.5 to 7.2% of human tuberculosis cases in industrialized nations and is estimated to be responsible for 10 to 15% of new cases in the developing world (13). Consistent with these estimates, M. bovis accounts for ϳ11% of pediatric tuberculosis cases along the California-Mexico border (11). In addition, there is an emerging problem of disseminated M. bovis BCG due to vaccination of neonates and children in endemic regions with high rates of vertical transmission of human immunodeficiency virus (HIV) (1, 18). Finally, ϳ1% of intravesical M. bovis BCG immunotherapy for bladder cancer results in disseminated disease (21). Thus, from a public health perspective, the natural history and control measures for disease differ substantially between complex members. For example, a diagnosis of M. bovis should prompt questions of zoonotic exposure or investigation into contamination of dairy products, the primary routes of human infection (16, 26). Therapeutically, both M. bovis and BCG are intrinsically resistant to pyrazinamide (PZA), a first-line antituberculosis agent, making their identification critical...